Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Zoetis (NYSE:ZTS) Share Price

Media stories about Zoetis (NYSE:ZTS) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.0052017913589 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Zoetis (NYSE:ZTS) opened at $74.59 on Friday. The company has a market capitalization of $36,350.00, a P/E ratio of 39.26, a PEG ratio of 1.91 and a beta of 1.06. Zoetis has a fifty-two week low of $52.00 and a fifty-two week high of $75.47. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a return on equity of 64.54% and a net margin of 21.97%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the company posted $0.52 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. sell-side analysts predict that Zoetis will post 2.37 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a yield of 0.68%. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date of this dividend is Thursday, January 18th. Zoetis’s dividend payout ratio is 22.11%.

A number of equities research analysts have recently commented on ZTS shares. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price target on shares of Zoetis in a research report on Tuesday, September 26th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Thursday, October 12th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Tuesday, October 24th. Finally, BMO Capital Markets set a $65.00 price objective on Zoetis and gave the stock a “hold” rating in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus price target of $71.28.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Zoetis (NYSE:ZTS) Share Price” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply